Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.41 |
| ▸ | PPARA | Q07869 | 12/20 | 0.41 |
| ▸ | PPARD | Q03181 | 3/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | ADA | P00813 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL5661465 | 1.00 | PPARG (0.41) | PPARGPPARAPPARDBCL2MCL1 | |
| Arginine SCHEMBL5661025 | 0.93 | PPARG (0.39) | PPARGPPARAPPARDADAMTNR1A | |
| SCHEMBL5661036 | 0.90 | PPARA (0.35) | PPARGPPARAPPARDBCL2MCL1 | |
| Arginine SCHEMBL5660225 | 0.88 | PPARG (0.42) | PPARGPPARAPPARDBCL2MCL1 | |
| Arginine SCHEMBL5660219 | 0.88 | PPARG (0.42) | PPARGPPARAPPARDBCL2MCL1 | |
| SCHEMBL5659260 | 0.86 | PPARG (0.51) | PPARGPPARAPPARDBCL2MCL1 | |
| SCHEMBL5661026 | 0.83 | MTNR1A (0.35) | PPARGPPARAPPARDADAMTNR1A | |
| Arginine SCHEMBL5660450 | 0.80 | PPARG (0.47) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| Arginine SCHEMBL5660445 | 0.80 | PPARG (0.47) | PPARGPPARAPPARDCYP4F2CYP4A11 | |
| Arginine SCHEMBL5658603 | 0.80 | PPARA (0.40) | PPARGPPARAPPARDCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | claimed |
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | GPR119, NR1H3, NR1H2 | PPARG 170/4885PPARA 251/4885PPARD 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.